CA2284122A1 - Activated vitamin k-dependent blood factor and method for the production thereof - Google Patents
Activated vitamin k-dependent blood factor and method for the production thereof Download PDFInfo
- Publication number
- CA2284122A1 CA2284122A1 CA002284122A CA2284122A CA2284122A1 CA 2284122 A1 CA2284122 A1 CA 2284122A1 CA 002284122 A CA002284122 A CA 002284122A CA 2284122 A CA2284122 A CA 2284122A CA 2284122 A1 CA2284122 A1 CA 2284122A1
- Authority
- CA
- Canada
- Prior art keywords
- factor
- protease
- activation
- blood factor
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 229960000182 blood factors Drugs 0.000 title claims abstract description 32
- 230000001419 dependent effect Effects 0.000 title claims abstract description 11
- 229940046010 vitamin k Drugs 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title description 6
- 239000004365 Protease Substances 0.000 claims abstract description 92
- 108091005804 Peptidases Proteins 0.000 claims abstract description 68
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 9
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 9
- 239000011712 vitamin K Substances 0.000 claims abstract description 9
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 15
- 230000004913 activation Effects 0.000 claims description 64
- 102000035195 Peptidases Human genes 0.000 claims description 53
- 108010014173 Factor X Proteins 0.000 claims description 47
- 235000019419 proteases Nutrition 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 34
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 claims description 27
- 235000018102 proteins Nutrition 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 108090000270 Ficain Proteins 0.000 claims description 25
- 235000019836 ficin Nutrition 0.000 claims description 25
- 241000196324 Embryophyta Species 0.000 claims description 17
- 229910001424 calcium ion Inorganic materials 0.000 claims description 12
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 9
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 7
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 6
- 101800004937 Protein C Proteins 0.000 claims description 4
- 101800001700 Saposin-D Proteins 0.000 claims description 4
- 108090001109 Thermolysin Proteins 0.000 claims description 4
- 229960000856 protein c Drugs 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 3
- 108090001092 clostripain Proteins 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 230000006337 proteolytic cleavage Effects 0.000 claims description 3
- 108010004032 Bromelains Proteins 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000000287 crude extract Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 6
- 238000011109 contamination Methods 0.000 abstract description 2
- 238000001994 activation Methods 0.000 description 58
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 40
- 108010074860 Factor Xa Proteins 0.000 description 28
- 239000000872 buffer Substances 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 238000011534 incubation Methods 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 108090001015 cancer procoagulant Proteins 0.000 description 14
- 238000010828 elution Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000012190 activator Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 108010094028 Prothrombin Proteins 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 102100027378 Prothrombin Human genes 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- 235000011148 calcium chloride Nutrition 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 229940039716 prothrombin Drugs 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- -1 pH 7.4 Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 5
- 229940038773 trisodium citrate Drugs 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- 241000271032 Daboia russelii Species 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- 102100035233 Furin Human genes 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 241001065700 Ficus glabrata Species 0.000 description 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 2
- DEOKFPFLXFNAON-UHFFFAOYSA-N N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193389 Bacillus thermoproteolyticus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 244000025361 Ficus carica Species 0.000 description 1
- 235000008730 Ficus carica Nutrition 0.000 description 1
- LSPKYLAFTPBWIL-BYPYZUCNSA-N Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(O)=O LSPKYLAFTPBWIL-BYPYZUCNSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108090000040 Russellysin Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical class C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000001470 plasma protein fractionation Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002821 viper venom Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19710190A DE19710190A1 (de) | 1997-03-12 | 1997-03-12 | Aktivierter Vitamin K-abhängiger Blutfaktor und Verfahren zu dessen Herstellung |
| DE19710190.9 | 1997-03-12 | ||
| PCT/EP1998/001364 WO1998040474A2 (de) | 1997-03-12 | 1998-03-10 | Aktivierter vitamin k-abhängiger blutfaktor und verfahren zu dessen herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2284122A1 true CA2284122A1 (en) | 1998-09-17 |
Family
ID=7823110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002284122A Abandoned CA2284122A1 (en) | 1997-03-12 | 1998-03-10 | Activated vitamin k-dependent blood factor and method for the production thereof |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0968280A1 (de) |
| JP (1) | JP2001514516A (de) |
| AU (1) | AU740727B2 (de) |
| CA (1) | CA2284122A1 (de) |
| DE (1) | DE19710190A1 (de) |
| HU (1) | HUP0001505A3 (de) |
| NO (1) | NO994394L (de) |
| SK (1) | SK124699A3 (de) |
| WO (1) | WO1998040474A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI684599B (zh) * | 2014-08-12 | 2020-02-11 | 美商巴克斯歐塔公司 | 因子ｘ活化 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3171072D1 (en) * | 1981-06-25 | 1985-07-25 | Stroetmann M Serapharm | Enriched plasma derivative for promoting wound sealing and wound covering |
| EP0485504B1 (de) * | 1989-08-11 | 1993-12-01 | Zymogenetics, Inc. | Zellenzuchtverfahren für die produktion von aktiviertem protein-c |
| ES2131504T3 (es) * | 1990-02-20 | 1999-08-01 | Baxter Int | Trombina humana purificada viricamente segura. |
| CA2121028A1 (en) * | 1991-10-11 | 1993-04-15 | Ulla K. E. Hedner | Hemostatic composition for local hemostasis |
| WO1993009807A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels |
| AU683834B2 (en) * | 1991-12-31 | 1997-11-27 | Zymogenetics Inc. | Methods for producing thrombin |
| AT397390B (de) * | 1992-04-06 | 1994-03-25 | Immuno Ag | Verfahren zur spaltung von proteinen |
| US5514373A (en) * | 1992-05-22 | 1996-05-07 | Harris, Jr.; Roosevelt D. | Topical preparation |
| WO1994021284A1 (en) * | 1993-03-15 | 1994-09-29 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
| DE4325872C1 (de) * | 1993-08-02 | 1994-08-04 | Immuno Ag | Virusinaktivierte Faktor Xa-Präparation |
| DE4430205A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
| US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| DE19503338C2 (de) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Arzneiform zur Abgabe von Kollagenase an Wunden und Verfahren zu ihrer Herstellung und ihre Verwendung |
-
1997
- 1997-03-12 DE DE19710190A patent/DE19710190A1/de not_active Withdrawn
-
1998
- 1998-03-10 AU AU68295/98A patent/AU740727B2/en not_active Ceased
- 1998-03-10 CA CA002284122A patent/CA2284122A1/en not_active Abandoned
- 1998-03-10 SK SK1246-99A patent/SK124699A3/sk unknown
- 1998-03-10 JP JP53920998A patent/JP2001514516A/ja active Pending
- 1998-03-10 EP EP98913692A patent/EP0968280A1/de not_active Withdrawn
- 1998-03-10 WO PCT/EP1998/001364 patent/WO1998040474A2/de not_active Ceased
- 1998-03-10 HU HU0001505A patent/HUP0001505A3/hu unknown
-
1999
- 1999-09-10 NO NO994394A patent/NO994394L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU740727B2 (en) | 2001-11-15 |
| SK124699A3 (en) | 2000-06-12 |
| WO1998040474A3 (de) | 1999-02-11 |
| NO994394L (no) | 1999-11-11 |
| NO994394D0 (no) | 1999-09-10 |
| HUP0001505A1 (hu) | 2000-09-28 |
| HUP0001505A3 (en) | 2002-01-28 |
| EP0968280A1 (de) | 2000-01-05 |
| WO1998040474A2 (de) | 1998-09-17 |
| JP2001514516A (ja) | 2001-09-11 |
| DE19710190A1 (de) | 1998-09-17 |
| AU6829598A (en) | 1998-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walker | Protein S and the regulation of activated protein C | |
| Kisiel et al. | [26] Protein C | |
| EP0332678A1 (de) | Mikrogrosses fibrinolytisches plasmin | |
| Morita et al. | Localization of the structural difference between bovine blood coagulation factors X1 and X2 to tyrosine 18 in the activation peptide. | |
| IL131171A (en) | Factor x deletion mutants and analogues thereof and preparations containing the same | |
| Volanakis et al. | Human factor D of the alternative complement pathway: purification and characterization | |
| Liska et al. | Location of. gamma.-carboxyglutamyl residues in partially carboxylated prothrombin preparations | |
| Morita et al. | Calcium binding to a human factor IXa derivative lacking γ-carboxyglutamic acid: evidence for two high-affinity sites that do not involve β-hydroxyaspartic acid | |
| Højrup et al. | Disulphide bridges of bovine factor X | |
| JPH0775572A (ja) | ウイルスを不活性化したＸａ因子調製物 | |
| Kisiel et al. | Proteolysis of human factor II by factor Xa in the presence of hirudin | |
| JP2832129B2 (ja) | 酵素的分解によるタンパク質の切断方法およびその利用方法 | |
| EP1238065A2 (de) | Faktor x-analoge mit verbesserter fähigkeit zur aktivierung | |
| Fujikawa et al. | [10] Bovine factor X (Stuart factor) | |
| JP2723445B2 (ja) | 血液凝固因子を活性化する方法 | |
| Briet et al. | Cleavage and activation of human prothrombin by Echiscarinatus venom | |
| AU740727B2 (en) | Activated vitamin K-dependent blood factor and method for the production thereof | |
| Samel et al. | Metalloproteinase with factor X activating and fibrinogenolytic activities from Vipera berus berus venom | |
| JP4180671B2 (ja) | タンパク質の調製および回収方法 | |
| CLAEYS et al. | Purification and Cahracterization of Bovine Coagulation Factor XII (Hageman Factor) | |
| Gilbert et al. | Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH: A comparison with human urokinase | |
| Rabiet et al. | Activation of prothrombin Barcelona evidence for active high molecular weight intermediates | |
| EP0416890A1 (de) | Verfahren zur Aktivierung von Protein C | |
| RU2167936C2 (ru) | Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с | |
| RU2112528C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ФЕРМЕНТА ДЕСТАБИЛАЗЫ, ОБЛАДАЮЩЕГО ФИБРИНОЛИТИЧЕСКОЙ, ТРОМБОЛИТИЧЕСКОЙ, ЭНДО- И ЭКЗО- ε(γ GLY)-LYS-ИЗОПЕПТИДАЗНОЙ И АМИДОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |